Pellegatta, S., Eoli, M., Cuccarini, V., Anghileri, E., Pollo, B., Pessina, S., . . . Finocchiaro, G. (2018). Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide. Oncoimmunology.
Chicago Style citaatPellegatta, Serena, et al. "Survival Gain in Glioblastoma Patients Treated With Dendritic Cell Immunotherapy Is Associated With Increased NK but Not CD8(+) T Cell Activation in the Presence of Adjuvant Temozolomide." Oncoimmunology 2018.
MLA citatiePellegatta, Serena, et al. "Survival Gain in Glioblastoma Patients Treated With Dendritic Cell Immunotherapy Is Associated With Increased NK but Not CD8(+) T Cell Activation in the Presence of Adjuvant Temozolomide." Oncoimmunology 2018.